EGFR and breast cancer: Our group modified 111In-labelled anti-EGFR mAb nimotuzumab with 13-mer peptides CGYGPKKKRKVGG that harbour the SV-40 large T-antigen-derived nuclear localisation sequence (NLS; italicised) and studied the cytotoxicity of these radioimmunoconjugates towards EGFR-positive breast cancer cells (Fasih et al. 2012).